DW 2143Alternative Names: DW-2143
Latest Information Update: 07 Feb 2008
At a glance
- Originator Dong Wha
- Developer Dong Wha Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Apr 2003 No development reported - Preclinical for Cancer in Japan (unspecified route)
- 10 Oct 1998 Preclinical development for Cancer in Japan (Unknown route)